CEO Of CytRx Is Interviewed By The Wall Street Transcript.Business Editors NORCROSS, Ga.--(BUSINESS WIRE)--Sept. 6, 2000 Jack Luchese, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CytRx Corporation (Nasdaq:CYTR CYTR Canadian Yorkshire Terrier Rescue CYTR Constant Yield Tax Rate (property tax) ), a small and emerging biopharmaceutical company, provided intriguing comments on the Company's efforts to develop and integrate drugs into the market through strategic partnerships during a recent interview with The Wall Street Transcript. During the insightful interview, Luchese provided an overview of CytRx and details of the Company's strong patent position and explained management's philosophy in the use of strategic partners. To obtain a complete transcript of the interview, please visit http://www.twst.com and execute a search for document no. KAM609. About The Wall Street Transcript The Wall Street Transcript is a premier weekly investment publication interviewing market professionals for serious investors for over 36 years. The Company's Web site is located at http://www.twst.com. The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations. About CytRx Corporation CytRx is a biopharmaceutical company focused on the development and commercialization of high-value human therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. . The Company's current research and development activities are focused primarily on two of its technologies - FLOCOR(TM), an intravenous agent for acute vaso-occlusive disorders and related acute care applications, and TRANZFECT, a DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. delivery technology which may have wide application in DNA vaccines and gene therapy. CytRx also has a research pipeline with opportunities in the areas of vaccine adjuvants, infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. , and food animal feed additives. Except for the historical information contained herein, the matter set forth in this news release may include forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. that are subject to risks and uncertainty that may cause actual results to differ materially. Such forward-looking statements that may be contained in this document could include in particular statements concerning business backlogs, operating efficiencies and capacities, capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. , and other expenses. Among other factors that could cause actual results to differ materially are the following: dependence upon unaffiliated manufacturers and fabric suppliers, dependence on certain customers, foreign operations, competition, risk associated with significant growth, uncertainties in the apparel industry, general economic conditions, seasonality, political instability, concentration of accounts receivable accounts receivable n. the amounts of money due or owed to a business or professional by customers or clients. Generally, accounts receivable refers to the total amount due and is considered in calculating the value of a business or the business' problems in paying , possible fluctuations in the operations in operating results. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion